SOLVO Biotechnology establishes US unit
Hungary's SOLVO Biotechnology has established a unit in the United States, the company told MTI.
SOLVO set up an office in Boston to meet growing market demand in the recent period, said business development director Berend Oosterhuis. Demand for the company's products has grown since the US Food and Drug Administration (FDA) introduced new directives requiring review of drug transporters – in which SOLVO specializes – as part of drug studies, he added.
SOLVO's revenue – all of it from exports – rose 50% last year, climbing over HUF 1 billion for the first time. This year, the company expects revenue to rise over 50%.
The company has more than 400 partners in 38 countries.
More than one-third of SOLVO's 90 staff have PhDs.
Moody's Affirms Budapest's 'Baa3' Rating
Bulgaria's Household Income, Spending Rise 20% in 2023
Job Fair and Career Prep at Corvinus Starts Tomorrow
Silvanus Hotel Under Reconstruction, Will Reopen in Fall
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
